Using Glycosylated Hemoglobin to Define the Metabolic Syndrome in United States Adults by Ong, Kwok Leung et al.
Using Glycosylated Hemoglobin to Deﬁne
the Metabolic Syndrome in United States
Adults
KWOK LEUNG ONG, MPHIL
1
ANNETTE W.K. TSO, MD
1,2
KAREN S.L. LAM, MD
1,2
STACEY S. CHERNY, PHD
3,4
PAK CHUNG SHAM, MD
3,4,5
BERNARD M.Y. CHEUNG, PHD
1,2
OBJECTIVE — To compare the use of GHb and fasting plasma glucose (FPG) to deﬁne the
metabolic syndrome (MetS).
RESEARCH DESIGN AND METHODS — Data from the U.S. National Health and
Nutrition Examination Survey 1999–2006 were used. MetS was deﬁned using the consensus
criteria in 2009. Raised blood glucose was deﬁned as either FPG 100 mg/dl (5.6 mmol/l) or
GHb 5.7%.
RESULTS — In 2003–2006, there was 91.3% agreement between GHb and FPG when either
was used to deﬁne MetS. The agreement was good irrespective of age, sex, race/ethnicity, BMI,
and diabetes status (87.4%). Similar results were found in 1999–2002. Among subjects
withoutdiabetes,onlytheuseofGHbalone,butnotFPG,resultedinsigniﬁcantassociationwith
cardiovascular diseases (odds ratio 1.45, P  0.005).
CONCLUSIONS — Using GHb instead of FPG to deﬁne MetS is feasible. It also identiﬁes
individuals with increased cardiovascular risk.
Diabetes Care 33:1856–1858, 2010
T
he metabolic syndrome (MetS) de-
scribes the clustering of closely re-
lated cardiovascular risk factors (1).
The deﬁnition of MetS, proposed in 2001
by the National Cholesterol Education
Program (NCEP) Expert Panel (2), was
later modiﬁed in accordance with the re-
vised deﬁnition of impaired fasting glu-
cose from the American Diabetes
Association (ADA) in 2004 (1,3). Re-
cently, a uniﬁed deﬁnition of MetS was
proposed jointly by several organizations
in 2009 (4), while ADA proposed the use
of GHb in the deﬁnition of diabetes and
the category of increased diabetes risk
(whichalsoincludesimpairedfastingglu-
cose and impaired glucose tolerance) in
2010 (5). Therefore, we investigated
whether GHb can be used instead of fast-
ing plasma glucose (FPG) in identifying
individuals with MetS.
RESEARCH DESIGN AND
METHODS— Data from the cross-
sectional U.S. National Health and Nutri-
tion Examination Survey (NHANES)
2003–2006 were used in initial analysis
(6). For conﬁrmation, we used the cross-
sectional data from NHANES 1999–
2002. All participants gave informed
consent, and the study received approval
from the Centers for Disease Control and
Prevention Institutional Review Board.
MetS was deﬁned using the consen-
sus criteria in 2009 (4). Under this deﬁ-
nition, a person has MetS if he or she
meets three or more of the following cri-
teria: 1) central obesity, deﬁned using
ethnic-speciﬁccutpointsofwaistcircum-
ference, 2) triglycerides 150 mg/dl (1.7
mmol/l), 3) HDL cholesterol 40 mg/dl
(1.0 mmol/l) in men and 50 mg/dl (1.3
mmol/l) in women, 4) blood pressure
130/85 mmHg or on antihypertensive
medication, or 5) raised blood glucose,
deﬁned as FPG 100 mg/dl (5.6 mmol/l)
or on antidiabetic medication. For non-
Hispanicwhitesandblacks,andpeopleof
other races and mixed races, the cut
points for waist circumference were 94
cm in men and 80 cm in women. For
Mexican Americans and other Hispanics,
the cut points were 90 cm in men and
80cminwomen.Inaseparateanalysis,
MetS was deﬁned using the NCEP crite-
ria,whichwerethesameastheconsensus
criteria in 2009 (4), except that central
obesity was deﬁned as waist circumfer-
ence 102 cm in men and 88 cm in
women (1,3). The uses of GHb 5.7% or
FPG 100 mg/dl in the deﬁnition of the
glycemic component of MetS were com-
pared. Agreement between two deﬁni-
tions was deﬁned as the percentage of
participants who were classiﬁed the same
under both deﬁnitions (7,8).
The laboratory methods have been
described in detail elsewhere (6,8–11).
Data on GHb and FPG were adjusted so
that measurements across survey periods
couldbecombined(6).Historyofcardio-
vascular diseases was obtained from
self-reported questionnaires. Statistical
analysis was performed using the com-
plex samples function of SPSS version
15.0 (SPSS, Chicago, IL). Fasting sam-
pling weights were used in all analyses to
adjust for oversampling and nonresponse
bias and to approximate the distribution
to the U.S. population in the year 2000.
RESULTS— After excluding pregnant
women and subjects with missing data in
BMI, GHb, and the ﬁve components of
MetS, there were 3,551 and 3,412 partic-
ipants aged 20 years in NHANES
1999–2002 and 2003–2006, respec-
tively, who had fasted for 8–24 h.
As shown in Table 1, in NHANES
2003–2006, the use of GHb alone re-
sulted in a lower percentage of people
meeting the glycemic criteria of MetS
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74.9% agreement between these two def-
initions. The use of GHb alone also re-
sulted in a lower prevalence of MetS
compared with the use of FPG alone (Ta-
ble 1). The use of both GHb and FPG
resulted in an insigniﬁcant increase in the
prevalence compared with the use of FPG
alone (41.1 vs. 38.8%, P  0.200). There
was 91.3% agreement between the use of
GHb alone and the use of FPG alone. The
agreement was good irrespective of age,
sex, race/ethnicity, and BMI. The same
trends were found in NHANES 1999–
2002 or when the NCEP deﬁnition was
used (see supplementary Tables A1 and
A2, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-0190/DC1).
Because there is controversy whether
the diagnosis of MetS conveys additional
meaning in subjects with diabetes who
shouldalreadybeaggressivelytreateddue
to high cardiovascular risk, a subgroup
without diabetes (non-DM) was also ex-
amined. Similar to the overall cohort, in
the non-DM group, the use of GHb alone
resultedinlowerprevalenceofMetScom-
pared with FPG alone, with 90.6% agree-
ment (Table 1). Importantly, in this
non-DM subgroup, only the use of GHb
alone, but not FPG, resulted in signiﬁcant
association with cardiovascular diseases
(odds ratio 1.45, P  0.005) when the
consensus criteria in 2009 was used to
deﬁne MetS (supplementary Table A3).
CONCLUSIONS — The controversy
regarding the deﬁnition of MetS has been
addressed recently in a joint scientiﬁc
statement (4). GHb reﬂects the average
blood glucose level over several months,
and its measurement does not require a
fasting blood sample. In this study, we
demonstrated that there was good agree-
ment between GHb and FPG in identify-
ing individuals with MetS, despite only a
moderate agreement (75%) between
GHb and FPG in deﬁning raised blood
glucose. The components of MetS are in-
ter-correlated; therefore, a certain degree
of inaccuracy or ﬂuctuation in one com-
ponent is tolerated and does not result in
misclassiﬁcation. The agreement between
GHb and FPG in the deﬁnition of MetS is
good in different subgroups. We can
therefore conﬁdently conclude that using
GHb instead of FPG to deﬁne MetS is fea-
sible. This is true at least for Americans,
based on the most up-to-date data on a
nationallyrepresentativesampleofAmer-
icans, and was conﬁrmed using historical
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sionsarealsoapplicabletoAsians,among
whom the prevalence of raised blood glu-
cose is likely to be different.
The current cut point of GHb identi-
ﬁes a slightly smaller group of people as
having MetS. However, it also identiﬁes
subjects at high risk for cardiovascular
diseases, even in those without diabetes,
when the consensus criteria in 2009 are
used to deﬁne MetS. Whether GHb re-
sults in better risk stratiﬁcation needs to
be investigated in large prospective
studies.
Acknowledgments— No potential conﬂicts
of interest relevant to this article were
reported.
K.L.O. researched data, contributed to dis-
cussion, and wrote the manuscript. A.W.K.T.
and K.S.L.L. contributed to discussion and re-
viewed/edited the manuscript. S.S.C. and
P.C.S. contributed to discussion. B.M.Y.C.
contributed to discussion, wrote the manu-
script, and reviewed/edited the manuscript.
References
1. Grundy SM, Cleeman JI, Daniels SR, Do-
nato KA, Eckel RH, Franklin BA, Gordon
DJ, Krauss RM, Savage PJ, Smith SC Jr,
Spertus JA, Costa F. Diagnosis and man-
agement of the metabolic syndrome: an
American Heart Association/National
Heart, Lung, and Blood Institute scien-
tiﬁc statement. Circulation 2005;112:
2735–2752
2. Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol
in Adults: Executive Summary of the
Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA 2001;
285:2486–2497
3. Grundy SM, Brewer HB Jr, Cleeman JI,
Smith SC Jr, Lenfant C, American Heart
Association, National Heart, Lung, and
Blood Institute. American Heart Associa-
tion; National Heart, Lung, and Blood In-
stitute.Deﬁnitionofmetabolicsyndrome:
Report of the National Heart, Lung, and
Blood Institute/American Heart Associa-
tionconferenceonscientiﬁcissuesrelated
to deﬁnition. Circulation 2004;109:433–
438
4. Alberti KG, Eckel RH, Grundy SM, Zim-
met PZ, Cleeman JI, Donato KA, Fruchart
JC, James WP, Loria CM, Smith SC Jr,
International Diabetes Federation Task
Force on Epidemiology and Prevention,
Hational Heart, Lung, and Blood Insti-
tute, American Heart Association, World
Heart Federation, International Athero-
sclerosis Society, International As-
sociation for the Study of Obesity. Har-
monizingthemetabolicsyndrome:ajoint
interim statement of the International Di-
abetesFederationTaskForceonEpidemi-
ology and Prevention; National Heart,
Lung, and Blood Institute; American
Heart Association; World Heart Federa-
tion; International Atherosclerosis Soci-
ety; and International Association for the
Study of Obesity. Circulation 2009;120:
1640–1645
5. American Diabetes Association. Stan-
dards of medical care in diabetes: 2010.
Diabetes Care 2010;33:S11–S61
6. Centers for Disease Control and Preven-
tion (CDC). National Center for Health
Statistics (NCHS): National Health and
Nutrition Examination Survey question-
naire, examination protocol and labora-
tory protocol. Hyattsville, MD, United
States Department of Health and Human
Services, Centers for Disease Control and
Prevention, 1999–2006. Available at
http://www.cdc.gov/nchs/nhanes.htm.
Accessed 16 November 2009
7. Ford ES, Giles WH. A comparison of the
prevalence of the metabolic syndrome us-
ing two proposed deﬁnitions. Diabetes
Care 2003;26:575–581
8. Cheung BM, Ong KL, Man YB, Wong LY,
Lau CP, Lam KS. Prevalence of the meta-
bolic syndrome in the United States Na-
tional Health and Nutrition Examination
Survey 1999–2002 according to different
deﬁningcriteria.JClinHypertens(Green-
wich) 2006;8:562–570
9. Ong KL, Tso AW, Lam KS, Cheung BM.
Gender difference in blood pressure con-
trol and cardiovascular risk factors in
Americans with diagnosed hypertension.
Hypertension 2008;51:1142–1148
10. Cheung BM, Ong KL, Cherny SS, Sham
PC, Tso AW, Lam KS. Diabetes preva-
lence and therapeutic target achievement
in the United States, 1999 to 2006. Am J
Med 2009;122:443–453
11. CowieCC,RustKF,Byrd-HoltDD,Gregg
EW, Ford ES, Geiss LS, Bainbridge KE,
Fradkin JE. Prevalence of diabetes and
highriskfordiabetesusingA1Ccriteriain
the U.S. population in 1988–2006. Dia-
betes Care 2010;33:562–568
GHb and the metabolic syndrome
1858 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.org